SCHEMBL757046

SCHEMBL757046

CS(=O)(=O)NCCC(=NNC(N)=S)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CTSL P07711 8/20 0.58
ATM Q13315 1/20 0.50
METTL3 Q86U44 1/20 0.50
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CTSB P07858 4/20 0.46
CTSK P43235 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755539 0.86 CTSL (0.56) CTSLATMMETTL3GAACTSB
SCHEMBL27627084 0.78 CTSL (0.69) CTSLATMMETTL3MAPTCTSB
SCHEMBL2675573 0.78 CTSL (0.73) CTSLATMMETTL3GAAMAPT
SCHEMBL7167509 0.77 CTSL (0.68) CTSLATMMETTL3GAAMAPT
SCHEMBL7167512 0.77 CTSL (0.68) CTSLATMMETTL3GAAMAPT
SCHEMBL757047 0.77 CTSL (0.55) CTSLATMMETTL3CTSBCTSK
SCHEMBL27647421 0.76 CTSL (0.71) CTSLATMMETTL3GAAMAPT
SCHEMBL758695 0.76 CTSL (0.54) CTSLATMMETTL3GAACTSB
SCHEMBL941477 0.76 CTSL (0.66) CTSLATMMETTL3GAAMAPT
SCHEMBL941478 0.76 CTSL (0.66) CTSLATMMETTL3GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318782-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-27 US disclosed
EP-1847534-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2012-03-21 EP disclosed
US-20110275827-A1 Mitotic Kinesin Inhibitor FUJIFILM CORPORATION (JP) 2011-11-10 US disclosed
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP disclosed
EP-1847534-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-06-22 EP disclosed
EP-2327702-A1 Mitotic kinesin inhibitor Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-7910611-B2 Therapeutic agent for restenosis KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-22 US disclosed
US-7902234-B2 Thiadiazoline derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-08 US disclosed
US-20110004000-A1 Mitotic Kinesin Inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-01-06 US disclosed
US-7851635-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-12-14 US disclosed
US-20080194653-A1 Therapeutic Agent For Solid Tumor KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-08-14 US disclosed
EP-1908755-A1 THERAPEUTIC AGENT FOR RESTENOSIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-04-09 EP disclosed
EP-1870404-A1 AGENT FOR TREATMENT OF HEMATOPOIETIC TUMOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-12-26 EP disclosed
EP-1867640-A1 AGENT FOR TREATMENT OF SOLID TUMOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-12-19 EP disclosed
EP-1847534-A2 Thiadiazoline derivative Kyowa Hakko Kogyo Co., Ltd (JP) 2007-10-24 EP disclosed
US-20070213380-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-09-13 US disclosed
US-20070155804-A1 Mitotic kinesin inhibitor KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN 2007-07-05 US disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1616866-A1 M-STAGE KINESIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 CTSL 4237/4885ATM 516/4885METTL3 2876/4885
US-20070155804-A1 Mitotic kinesin inhibitor KIF15, KIF5A, KIF5B CTSL 4128/4885ATM 648/4885METTL3 4203/4885
US-20070213380-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 CTSL 4237/4885ATM 516/4885METTL3 2876/4885
US-20110004000-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B CTSL 4128/4885ATM 648/4885METTL3 4203/4885
US-20080194653-A1 Therapeutic Agent For Solid Tumor HRH3, TP53, VHL CTSL 2714/4885ATM 1835/4885METTL3 3171/4885
US-20110275827-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B CTSL 4128/4885ATM 648/4885METTL3 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.